Correlation between MMP-9 and extracellular cytokine HMGB1 in prediction of human ischemic stroke outcome

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1379-1384

  Sapojnikova, Nelly ^a   Kartvelishvili, Tamar ^a   Asatiani, Nino ^a   Zinkevich, Vitaly ^b   Kalandadze, Iagor ^a   Gugutsidze, Darejan ^a   Shakarishvili, Roman ^a   Tsiskaridze, Alexander ^a  

^a TBILISI STATE UNIVERSITY   (Georgia)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Gelatin zymography; HMGB1; Human ischemic stroke; Matrix metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; MACROPHAGE ELASTASE;

ADULT; AGED; ARTICLE; BRAIN CIRCULATION; BRAIN INFARCTION; BRAIN ISCHEMIA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLASGOW OUTCOME SCALE; HEART MUSCLE ISCHEMIA; HUMAN; LUNG ALVEOLUS MACROPHAGE; MALE; MOLECULAR WEIGHT; MOYAMOYA DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPROTECTION; OXFORDSHIRE COMMUNITY STROKE PROJECT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE PATIENT; ZYMOGRAPHY;

GELATIN ZYMOGRAPHY; HMGB1; HUMAN ISCHEMIC STROKE; MATRIX METALLOPROTEINASES;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; PROGNOSIS; STROKE;

EID: 84903641439     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.04.031     Document Type: Article

References (25)

1. Frankowski H., Gu Y.-H., Heo J.H., Milner R., del Zoppo G.J. Use of gel zymography to examine matrixmetalloproteinase (gelatinase) expression in brain tissue or in primary glial cultures. Matrix Metalloproteinase Protocols: (Methods in Molecular Biology) 2010, vol. 622:221-233. Springer-Verlag Inc., New York. I.M. Clark (Ed.).
2. Lakhan S.E., Kirchgessner A., Tepper D., Leonard A. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front. Neurol. 2013, 4:1-15. (Article 32).
3. Jin R., Yang G., Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol. Dis. 2010, 38:376-385.
4. Yang Q.-W., Wang J.-Z., Li J.-C., Zhou Yu, Zhong Qi, Lu F.-L., Xiang J. High-mobility group protein box-1 and its relevance to cerebral ischemia. J. Cereb. Blood Flow Metab. 2010, 30:243-254.
5. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
6. Yang H., Tracey K.J. Targeting HMGB1 in inflammation. Biochim. Biophys. Acta 2010, 1799:149-156.
7. Muller S., Ronfani L., Bianchi M.E. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J. Intern. Med. 2004, 255:332-343.
8. Verma R.P., Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg. Med. Chem. 2007, 15:2223-2268.
9. Gerlach R.F., Uzuelli J.A., Souza-Tarla C.D., Tanus-Santos J.E. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and (MMP)-9 activities. Anal. Biochem. 2005, 344:147-149.
10. Goldstein R.S., Gallowitsch-Puerta M., Yang L.-H., Rosas-Ballina M., Huston J.M., Czura C.J., Lee D.C., Ward M.F., Bruchfeld A.N., Wang H., Lesser M.L., Church A.L., Litroff A.H., Sama A.E., Tracey K.J. Elevated High-Mobility Group Box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006, 25:571-574.
11. Kang H.-S., Kim J.H., Phi J.H., Kim Y.-Y., Kim J.E., Wang K.-C., Cho B.-K., Kim S.-K. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J. Neurol. Neurosurg. Psychiatry 2010, 81:673-678.
12. Chen Y.E. MMP-12, an old enzyme plays a new role in the pathogenesis of rheumatoid arthritis?. Am. J. Pathol. 2004, 165:1069-1070.
13. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nat./Mol. Cell Biol. 2007, 8:221-233.
14. Fisher J.F., Mobashery S. Mechanism-based profiling of MMPs. Matrix Metalloproteinase Protocols: (Methods in Molecular Biology) 2010, vol. 622:471-487. Springer-Verlag Inc., New York.
15. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., Meyer J. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
16. Rosell A., Alvarez-Sabín J., Arenillas J.F., Rovira A., Delgado P., Fernández-Cadenas I., Penalba A., Molina C.A., Montaner J. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 2005, 36:1415-1420.
17. Montaner J., Alvarez-Sabín J., Molina C.A., Anglés A., Abilleira S., Arenillas J., González M.A., Monasterio J. Matrix metalloproteinase expression after human cardioembolic stroke. Stroke 2001, 32:1759-1766.
18. Montaner J., Alvarez-Sabín J., Molina C.A., Anglés A., Abilleira S., Arenillas J., Monasterio J. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001, 32:2762-2767.
19. Graham C.A., Chan R.W.Y., Chan D.Y.S., Chan C.P.Y., Wong L.K.S., Rainer T.H. Matrix metalloproteinase 9 mRNA: an early prognostic marker for patients with acute stroke. Clin. Biochem. 2012, 45:352-355.
20. Huang J.-M., Hu J., Chen N., Hu M.-L. Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke. J. Crit. Care 2013, 28:792-797.
21. Schulze J., Zierath D., Tanzi P., Cain K., Shibata D., Dressel A., Becker K. Severe stroke induces long-lasting alterations of high-mobility group box 1. Stroke 2013, 44:246-248.
22. Sapojnikova N., Asatiani N., Kartvelishvili T., Kalandadze I., Tsiskaridze A. Plasma antioxidant activity as a marker for a favourable outcome in acute ischemic stroke. Antioxidant enzyme 2012, 141-168. InTech Inc., Croatia. M.A. El-Missiry (Ed.).
23. Li J., Kokkola R., Tabibzadeh S., Yang R., Ochani M., Qiang X., Harris H.E., Czura C.J., Wang H., Ulloa L., Wang H., Warren H.S., Moldawer L.L., Fink M.P., Andersson U., Tracey K.J., Yang H. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med. 2003, 9:37-45.
24. Haorah J., Ramirez S.H., Schall K., Smith D., Pandya R., Persidsky Yu. Oxidative stress activates protein tyrosine kinase and matrixmetalloproteinases leading to blood-brain barrier dysfunction. J. Neurochem. 2007, 101:566-576.
25. Kelly P.J., Morrow J.D., Ning M.M., Koroshetz W., Lo E.H., Terry E., Milne G.L., Hubbard J., Lee H., Stevenson E., Lederer M., Furie K.L. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke. Stroke 2008, 39:100-104.